Commercial ReadinessADAP management expressed confidence in the company's manufacturing capabilities and commercial readiness, indicating a strong potential for successful product launch.
Market OpportunityManagement reiterated market sizing assumptions with an estimate of up to $400M U.S. peak sales for both afami-cel and lete-cel combined, showcasing the significant commercial potential.
Regulatory MilestoneThe FDA accepted the BLA for Afami-cel in advanced synovial sarcoma and granted priority review, signifying a significant step towards market entry.